Recently, Melnick and colleagues developed a clinical-grade SIRT3-selective inhibitor, YC8-02, for specific targeting of mitochondrial SIRT3 in DLBCL because SIRT3 was found to be dispensable for normal cells22. This evidence concerns the gene SIRT3 and diffuse large B-cell lymphoma.